In comparison with conventional therapy, XMLI plus conventional therapy could significantly decrease serum BNP in CHF patients (MD − 149.59, 95% CI − 211.31 to − 87.88, P < 0.00001, Figure 6A). This evidence concerns the gene NPPB and congestive heart failure.